ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

All articles

Poster Presentation1 min read

SDE-100 a stochastic cysteine linked Vedotin ADC: Assessing comparability of extent and site of conjugation using multiple orthogonal analytical approaches Read more

Poster Presentation1 min read

SDE-100 a stochastic cysteine linked Vedotin ADC: Assessing comparability of higher order structure using multiple orthogonal analytical approaches Read more

Photo of manufacturing suite at Radiofilum's Deeside, Wales facility

News2 min read

Radiofilum Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK Read more

360 Virtual Tour1 min read

Radiofilum's Deeside Facility Virtual Tour Read more

One pager2 min read

Disulfide bond mapping of a monoclonal therapeutic antibody Read more

Picture from within Radiofilum's ADC development and manufacturing facility in Deeside, Wales showing two people within an ADC manufacturing suite

Webinar25 min read

Phase I ADC development and manufacturing: A case study Read more

Picture of Chris Nortcliffe, Mass Spectrometry Manager at Radiofilum's Deeside, Wales facility

Spotlight6 min read

Scientist Snapshot | Chris Nortcliffe, Mass Spectrometry Manager Read more

Picture of Stephanie Johnson, Senior Development Scientist

Spotlight5 min read

Scientist Snapshot | Stephanie Johnson, Senior Development Scientist Read more

One pager2 min read

Total antibody quantification of an ADC after plasma incubation

A key feature of monoclonal antibody (mAb) proteins is their stability in plasma due to their resistance to proteases.

Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Phone

This field is for validation purposes and should be left unchanged.

Service. Passion. Science.

PDMO^®

PDMO^® of Radiofilum Pharmaceutical Solutions Limited (EUIPO and UKIPO). All rights reserved.

Radiofilum Pharmaceutical Solutions Limited..